Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel J Hodson

Showing results (41-50 of 59) with videos related to

Pageof 6
Sort By:
Nature Communications|October 6, 2019
Genetic modification of primary human B cells to model high-grade lymphomaRebecca Caeser, Miriam Di Re, Joanna A Krupka, et al.
Blood|April 21, 2026
Mosunetuzumab plus polatuzumab vedotin in relapsed/refractory MCL after BTK inhibitor therapy: a phase 2 studyLihua E Budde, Manali Kamdar, Sarit E Assouline, et al.
Nature|August 10, 2022
Diverse mutational landscapes in human lymphocytesHeather E Machado, Emily Mitchell, Nina F Øbro, et al.
Molecular Cancer|October 16, 2021
DDX3X loss is an adverse prognostic marker in diffuse large B-cell lymphoma and is associated with chemoresistance in aggressive non-Hodgkin lymphoma subtypesAtish Kizhakeyil, Nurmahirah Binte Mohammed Zaini, Zhi Sheng Poh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 8, 2021
Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent LymphomaNathan H Fowler, Felipe Samaniego, Wojciech Jurczak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 22, 2025
Phased Variant-Supported Circulating Tumor DNA as a Prognostic Biomarker After First-Line Treatment in Large B-Cell Lymphoma: Findings From the DIRECT StudyJoanna A Krupka, Ilias Moutsopoulos, Natasha H Cutmore, et al.
Cancer Cell|January 12, 2024
Response to Bruton's tyrosine kinase inhibitors in aggressive lymphomas linked to chronic selective autophagyJames D Phelan, Sebastian Scheich, Jaewoo Choi, et al.
Blood Advances|August 10, 2022
Longitudinal expression profiling identifies a poor risk subset of patients with ABC-type diffuse large B-cell lymphomaFindlay Bewicke-Copley, Koorosh Korfi, Shamzah Araf, et al.
Nature Genetics|July 31, 2025
Author Correction: The long-term effects of chemotherapy on normal blood cellsEmily Mitchell, My H Pham, Anna Clay, et al.
Nature Genetics|July 2, 2025
The long-term effects of chemotherapy on normal blood cellsEmily Mitchell, My H Pham, Anna Clay, et al.
Pageof 6

Showing results (41-50 of 59) with videos related to

Sort By:
Pageof 6
Nature Communications|October 6, 2019
Genetic modification of primary human B cells to model high-grade lymphomaRebecca Caeser, Miriam Di Re, Joanna A Krupka, et al.
Blood|April 21, 2026
Mosunetuzumab plus polatuzumab vedotin in relapsed/refractory MCL after BTK inhibitor therapy: a phase 2 studyLihua E Budde, Manali Kamdar, Sarit E Assouline, et al.
Nature|August 10, 2022
Diverse mutational landscapes in human lymphocytesHeather E Machado, Emily Mitchell, Nina F Øbro, et al.
Molecular Cancer|October 16, 2021
DDX3X loss is an adverse prognostic marker in diffuse large B-cell lymphoma and is associated with chemoresistance in aggressive non-Hodgkin lymphoma subtypesAtish Kizhakeyil, Nurmahirah Binte Mohammed Zaini, Zhi Sheng Poh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 8, 2021
Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent LymphomaNathan H Fowler, Felipe Samaniego, Wojciech Jurczak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 22, 2025
Phased Variant-Supported Circulating Tumor DNA as a Prognostic Biomarker After First-Line Treatment in Large B-Cell Lymphoma: Findings From the DIRECT StudyJoanna A Krupka, Ilias Moutsopoulos, Natasha H Cutmore, et al.
Cancer Cell|January 12, 2024
Response to Bruton's tyrosine kinase inhibitors in aggressive lymphomas linked to chronic selective autophagyJames D Phelan, Sebastian Scheich, Jaewoo Choi, et al.
Blood Advances|August 10, 2022
Longitudinal expression profiling identifies a poor risk subset of patients with ABC-type diffuse large B-cell lymphomaFindlay Bewicke-Copley, Koorosh Korfi, Shamzah Araf, et al.
Nature Genetics|July 31, 2025
Author Correction: The long-term effects of chemotherapy on normal blood cellsEmily Mitchell, My H Pham, Anna Clay, et al.
Nature Genetics|July 2, 2025
The long-term effects of chemotherapy on normal blood cellsEmily Mitchell, My H Pham, Anna Clay, et al.
Pageof 6